Last reviewed · How we verify
ELIXCYTE
ELIXCYTE is an autologous cell therapy that expands and reinfuses a patient's own immune cells to enhance anti-tumor immunity.
ELIXCYTE is an autologous cell therapy that expands and reinfuses a patient's own immune cells to enhance anti-tumor immunity. Used for Solid tumors (specific indications under investigation in Phase 3).
At a glance
| Generic name | ELIXCYTE |
|---|---|
| Sponsor | UnicoCell Biomed CO. LTD |
| Drug class | Autologous cell therapy |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ELIXCYTE involves ex vivo expansion of patient-derived immune cells, likely T cells or natural killer cells, which are then reinfused to boost the body's ability to recognize and eliminate cancer cells. This approach leverages the patient's own immune system without genetic modification, aiming to provide durable anti-tumor responses.
Approved indications
- Solid tumors (specific indications under investigation in Phase 3)
Common side effects
- Cytokine release syndrome
- Infusion-related reactions
- Fatigue
Key clinical trials
- Efficacy and Safety of ELIXCYTE Intra-articular Injection in Subject With Knee Osteoarthritis (PHASE3)
- Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease (PHASE1, PHASE2)
- Adipose-derived Stem Cells (ADSCs) for Knee Osteoarthritis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ELIXCYTE CI brief — competitive landscape report
- ELIXCYTE updates RSS · CI watch RSS
- UnicoCell Biomed CO. LTD portfolio CI